Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281753 | 0.80 | GAA (0.52) | L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2278652 | 0.79 | MEN1 (0.47) | SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL31254060 | 0.79 | MEN1 (0.47) | SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL3966984 | 0.76 | CA12 (0.45) | SMN1; SMN2KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL2133031 | 0.76 | PTPN1 (0.52) | SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2491906 | 0.76 | MBTD1 (0.54) | ENPP1HRH3KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL1929030 | 0.76 | LTA4H (0.50) | HRH3SMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL4141829 | 0.75 | AR (0.49) | SMN1; SMN2KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL19733679 | 0.74 | MBTD1 (0.55) | ENPP1HRH3KCNH2SMN1; SMN2L3MBTL1 | |
| SCHEMBL11471531 | 0.74 | MBTD1 (0.50) | ENPP1HRH3KCNH2SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | ENPP1 2198/4885HRH3 159/4885KCNH2 1660/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | ENPP1 1726/4885HRH3 1028/4885KCNH2 2527/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | ENPP1 2198/4885HRH3 159/4885KCNH2 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.